Brimonidine

Drug Profile

Brimonidine

Alternative Names: AGN 190342; AGN 190342LF; Aiphagan Ophthalmic Solution 0.1%; Alphagan; Alphagan P; Alphagan Z; Brimonidine tartrate; DE 087; SNJ-2022; UK 1430 18; UK 14304

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Allergan; Senju Pharmaceutical
  • Class Antiglaucomas; Antihypertensives; Quinoxalines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase II Dry age-related macular degeneration
  • No development reported Retinal detachment; Retinitis pigmentosa
  • Discontinued Neurological disorders

Most Recent Events

  • 28 Sep 2015 Senju Pharmaceutical and Kanto Central Hospital of the Mutual Aid Association of Public School Teachers complete an exploratory phase II trial in Glaucoma and Ocular hypertension (In adults, In the elderly) in Japan (Topical) (UMIN000019142)
  • 31 Aug 2015 Phase-II development is ongoing for Dry age-related macular degeneration in World (Implant)
  • 31 Aug 2015 No recent reports on development identified - Phase-I/II for Retinitis pigmentosa in USA, France, Germany, Portugal (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top